<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<?properties open_access?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">Pharmgenomics Pers Med</journal-id>
<journal-id journal-id-type="iso-abbrev">Pharmgenomics Pers Med</journal-id>
<journal-id journal-id-type="publisher-id">Pharmacogenomics and Personalized Medicine</journal-id>
<journal-title-group>
<journal-title>Pharmacogenomics and Personalized Medicine</journal-title>
</journal-title-group>
<issn pub-type="epub">1178-7066</issn>
<publisher>
<publisher-name>Dove Medical Press</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">30050316</article-id>
<article-id pub-id-type="pmc">6055890</article-id>
<article-id pub-id-type="doi">10.2147/PGPM.S171423</article-id>
<article-id pub-id-type="publisher-id">pgpm-11-121</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Original Research</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>The functional variant rs334558 of <italic>GSK3B</italic> is associated with remission in patients with depressive disorders</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" equal-contrib="yes">
<name>
<surname>Levchenko</surname>
<given-names>Anastasia</given-names>
</name>
<xref ref-type="aff" rid="af1-pgpm-11-121">1</xref>
<xref ref-type="author-notes" rid="fn1-pgpm-11-121">*</xref>
<xref ref-type="corresp" rid="c1-pgpm-11-121"></xref>
</contrib>
<contrib contrib-type="author" equal-contrib="yes">
<name>
<surname>Losenkov</surname>
<given-names>Innokentiy S</given-names>
</name>
<xref ref-type="aff" rid="af2-pgpm-11-121">2</xref>
<xref ref-type="author-notes" rid="fn1-pgpm-11-121">*</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Vyalova</surname>
<given-names>Natalia M</given-names>
</name>
<xref ref-type="aff" rid="af2-pgpm-11-121">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Simutkin</surname>
<given-names>German G</given-names>
</name>
<xref ref-type="aff" rid="af2-pgpm-11-121">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Bokhan</surname>
<given-names>Nikolay A</given-names>
</name>
<xref ref-type="aff" rid="af2-pgpm-11-121">2</xref>
<xref ref-type="aff" rid="af3-pgpm-11-121">3</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Wilffert</surname>
<given-names>Bob</given-names>
</name>
<xref ref-type="aff" rid="af4-pgpm-11-121">4</xref>
<xref ref-type="aff" rid="af5-pgpm-11-121">5</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Loonen</surname>
<given-names>Anton JM</given-names>
</name>
<xref ref-type="aff" rid="af4-pgpm-11-121">4</xref>
<xref ref-type="aff" rid="af6-pgpm-11-121">6</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Ivanova</surname>
<given-names>Svetlana A</given-names>
</name>
<xref ref-type="aff" rid="af2-pgpm-11-121">2</xref>
<xref ref-type="aff" rid="af7-pgpm-11-121">7</xref>
</contrib>
</contrib-group>
<aff id="af1-pgpm-11-121">
<label>1</label>Institute of Translational Biomedicine, Saint Petersburg State University, Saint Petersburg, Russia, <email>a.levchenko@spbu.ru</email></aff>
<aff id="af2-pgpm-11-121">
<label>2</label>Mental Health Research Institute, Tomsk National Research Medical Center of the Russian Academy of Sciences, Tomsk, Russia</aff>
<aff id="af3-pgpm-11-121">
<label>3</label>Department of Psychotherapy and Psychological Counseling, National Research Tomsk State University, Tomsk, Russia</aff>
<aff id="af4-pgpm-11-121">
<label>4</label>Groningen Research Institute of Pharmacy, University of Groningen, Groningen, the Netherlands</aff>
<aff id="af5-pgpm-11-121">
<label>5</label>University Medical Center Groningen, University of Groningen, Groningen, the Netherlands</aff>
<aff id="af6-pgpm-11-121">
<label>6</label>GGZ Westelijk Noord-Brabant, Bergen op Zoom, the Netherlands</aff>
<aff id="af7-pgpm-11-121">
<label>7</label>Division for Control and Diagnostics, School of Non-Destructive Testing &amp; Security, National Research Tomsk Polytechnic University, Tomsk, Russia</aff>
<author-notes>
<corresp id="c1-pgpm-11-121">Correspondence: Anastasia Levchenko, Institute of Translational Biomedicine, Saint Petersburg State University, 7/9 Universitetskaya Embankment, Saint, Petersburg 199034, Russia, Tel +7 812 363 6939, Email <email>a.levchenko@spbu.ru</email></corresp>
<fn id="fn1-pgpm-11-121">
<label>*</label>
<p>These authors contributed equally to this work</p>
</fn>
</author-notes>
<pub-date pub-type="collection">
<year>2018</year>
</pub-date>
<pub-date pub-type="epub">
<day>20</day>
<month>7</month>
<year>2018</year>
</pub-date>
<volume>11</volume>
<fpage>121</fpage>
<lpage>126</lpage>
<permissions>
<copyright-statement>© 2018 Levchenko et al. This work is published and licensed by Dove Medical Press Limited</copyright-statement>
<copyright-year>2018</copyright-year>
<license>
<license-p>The full terms of this license are available at <ext-link ext-link-type="uri" xlink:href="https://www.dovepress.com/terms.php">https://www.dovepress.com/terms.php</ext-link> and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc/3.0/">http://creativecommons.org/licenses/by-nc/3.0/</ext-link>). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.</license-p>
</license>
</permissions>
<abstract>
<sec>
<title>Purpose</title>
<p><italic>GSK3B</italic> and <italic>AKT1</italic> genes have been implicated in the pathogenesis of a number of psychiatric and neurological disorders. Furthermore, their genetic variants are associated with response to antidepressant pharmacotherapy. As the evidence is still incomplete and inconsistent, continuing efforts to investigate the role of these two genes in the pathogenesis and treatment of brain disorders is necessary. The aim of our study was thus to evaluate the association of variants of these two genes with depressive disorders and drug treatment response.</p>
</sec>
<sec>
<title>Patients and methods</title>
<p>In the present study, 222 patients with a depressive disorder who underwent pharmacological antidepressant treatment were divided into remitters and non-remitters following a 28-day course of pharmacotherapy. The association of a depressive disorder and remission rates with polymorphisms rs334558 in the <italic>GSK3B</italic> gene and rs1130214 and rs3730358 in the <italic>AKT1</italic> gene was evaluated with a chi-square test.</p>
</sec>
<sec>
<title>Results</title>
<p>Neither of the studied genetic variants was associated with a depressive disorder. Furthermore, frequencies of alleles and genotypes for rs1130214 and rs3730358 were not different in the groups of remitters and non-remitters. However, the activating allele T of the functional polymorphism rs334558 was significantly associated with remission, when all types of antidepressant drugs were included. This association continued as a trend when only patients taking selective serotonin reuptake inhibitors were considered.</p>
</sec>
<sec>
<title>Conclusion</title>
<p>The present study provides support that the functional polymorphism rs334558 of <italic>GSK3B</italic> may play a role as a useful genetic and pharmacogenetic biomarker in the framework of personalized medicine approach.</p>
</sec>
</abstract>
<kwd-group>
<title>Keywords</title>
<kwd>depressive disorder</kwd>
<kwd>association study</kwd>
<kwd>
<italic>AKT1</italic>
</kwd>
<kwd>
<italic>GSK3B</italic>
</kwd>
<kwd>genetic biomarker</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec sec-type="intro">
<title>Introduction</title>
<p>Depressive disorders are the third leading cause of disability worldwide, according to a 2015 report.<xref ref-type="bibr" rid="b1-pgpm-11-121">1</xref> The phenotype is complex, indicating the existence of numerous types and subtypes,<xref ref-type="bibr" rid="b2-pgpm-11-121">2</xref> as are genetic factors contributing to these disorders.<xref ref-type="bibr" rid="b3-pgpm-11-121">3</xref>–<xref ref-type="bibr" rid="b5-pgpm-11-121">5</xref> Inheritance of one type, major depressive disorder (MDD), is only 30–40%, as was shown by twin studies.<xref ref-type="bibr" rid="b6-pgpm-11-121">6</xref>,<xref ref-type="bibr" rid="b7-pgpm-11-121">7</xref> Therefore, environmental factors, translated as epigenetics, must play a substantial role in the etiology.<xref ref-type="bibr" rid="b8-pgpm-11-121">8</xref>,<xref ref-type="bibr" rid="b9-pgpm-11-121">9</xref> Despite the apparent difficulties in the study of genetics of depressive disorders, there have been some breakthroughs in the last several years.<xref ref-type="bibr" rid="b4-pgpm-11-121">4</xref> An apparent reason that replicable results in genetic studies of depressive disorders have been difficult to achieve is that the patients constitute a very heterogeneous group and the most appropriate approach would be to view depressive disorders from the angle of personalized medicine.<xref ref-type="bibr" rid="b10-pgpm-11-121">10</xref>–<xref ref-type="bibr" rid="b19-pgpm-11-121">19</xref> An example of personalized approach is Research Domain Criteria that take account of molecular factors in the pathogenesis of mental illnesses.<xref ref-type="bibr" rid="b20-pgpm-11-121">20</xref>–<xref ref-type="bibr" rid="b22-pgpm-11-121">22</xref> This approach is particularly relevant, given the fact that, for example, MDD is pharmacotherapy-resistant in 30–40% of cases.<xref ref-type="bibr" rid="b23-pgpm-11-121">23</xref> Indeed, without understanding the precise etiopathological mechanisms in different groups of patients, it will not be possible to treat these disorders efficiently.</p>
<p>An important volume of pharmacogenetic studies of depressive disorders exists, including genome-wide association studies and case–control association studies using candidate genes<xref ref-type="bibr" rid="b24-pgpm-11-121">24</xref>–<xref ref-type="bibr" rid="b28-pgpm-11-121">28</xref> (pharmacoepigenetics of depressive disorders is also a developing field<xref ref-type="bibr" rid="b29-pgpm-11-121">29</xref>). One of the candidate genes used in pharmacogenetic studies in psychiatry is <italic>AKT1</italic>, a gene implicated in the pathogenesis of psychiatric disorders and response to medication via the AKT/GSK3 pathway.<xref ref-type="bibr" rid="b28-pgpm-11-121">28</xref>,<xref ref-type="bibr" rid="b30-pgpm-11-121">30</xref>–<xref ref-type="bibr" rid="b34-pgpm-11-121">34</xref> Single nucleotide polymorphisms (SNPs) rs1130214 and rs3730358 in this gene were investigated in the present study because of association of the TC haplotype with lower protein levels of AKT1, which suggests impaired mRNA expression or processing.<xref ref-type="bibr" rid="b34-pgpm-11-121">34</xref> In addition, SNP rs3730358 was found to be associated with late-onset depression.<xref ref-type="bibr" rid="b35-pgpm-11-121">35</xref> Another candidate gene is <italic>GSK3B</italic>, one of the major regulators of multiple molecular pathways, including WNT<xref ref-type="bibr" rid="b36-pgpm-11-121">36</xref>,<xref ref-type="bibr" rid="b37-pgpm-11-121">37</xref> and AKT/GSK3 pathways.<xref ref-type="bibr" rid="b30-pgpm-11-121">30</xref>,<xref ref-type="bibr" rid="b32-pgpm-11-121">32</xref> In fact, implication of GSK3B and of its pathways in psychiatric disorders has been extensively investigated.<xref ref-type="bibr" rid="b32-pgpm-11-121">32</xref>–<xref ref-type="bibr" rid="b34-pgpm-11-121">34</xref>,<xref ref-type="bibr" rid="b38-pgpm-11-121">38</xref>–<xref ref-type="bibr" rid="b48-pgpm-11-121">48</xref> This gene is directly or indirectly inhibited by antipsychotics, lithium, and antidepressants.<xref ref-type="bibr" rid="b30-pgpm-11-121">30</xref>,<xref ref-type="bibr" rid="b31-pgpm-11-121">31</xref> The variant rs334558, found in the promoter of <italic>GSK3B</italic>, is known to be functional, as it determines the expression level of <italic>GSK3B</italic>, possibly by regulating the transcription factor binding to the promoter.<xref ref-type="bibr" rid="b49-pgpm-11-121">49</xref> In particular, the allele T is associated with a 1.4-fold increased transcriptional strength, compared to the ancestral allele C, apparently because the nucleotide T creates a new binding site at the promoter for the transcription factor AP4.</p>
<p>In the present study, we report the association of remission following pharmacological antidepressant treatment with the functional SNP rs334558. Other SNPs and phenotypes showed no association.</p>
</sec>
<sec sec-type="methods|subjects">
<title>Patients and methods</title>
<sec sec-type="methods|subjects">
<title>Study subjects</title>
<p>The study was carried out in accordance with The Code of Ethics of the World Medical Association (Declaration of Helsinki 1975, revised in Fortaleza, Brazil, 2013) for experiments involving humans. After approval of the study protocol by the Local Bioethics Committee of the Mental Health Research Institute in Tomsk, Russia (Siberian region), 222 patients were recruited from an inpatient facility of the same institute. One hundred and twenty-seven control subjects without psychiatric disorders were also recruited into the study. Only subjects of European ancestry were considered. All subjects gave written informed consent after a proper explanation of the prospective study.</p>
<p>In particular, we included patients with a depressive disorder, determined using the following diagnostic criteria of the <italic>International Statistical Classification of Diseases and Related Health Problems, 10th Revision</italic> (ICD-10): depressive episode (ICD-10: F32, 44.4%), recurrent depressive disorder (ICD-10: F33, 34.4%), bipolar disorder (ICD-10: F31, 15.3%), and dysthymia (ICD-10: F34.1, 2.9%). The available demographic data comprised age (18–70 years or 49.93 ± 10.76 years), gender (177 women and 45 men), education (university 43.8%, professional college 44.4%, secondary school 11.8%), employment (employed 68.4%, unemployed or retired 31.6%), and marital status (married 53.2%, widowed 19.3%, divorced 17%, single 10.5%).</p>
<p>Clinical and demographic data were initially recorded in hard-copy medical files by psychiatrists at the Department of Affective Disorders of the Mental Health Research Institute in Tomsk, and this work was supervised by Dr. German Simutkin. These collected data were then transferred to a digital file (an electronic database) and were extracted from it during our study.</p>
<p>During their follow-up in the clinic, patients were given several different groups of antidepressants: selective serotonin reuptake inhibitors (SSRIs) (escitalopram, fluoxetine, paroxetine, fluvoxamine, sertraline, citalopram) (57.9% of patients), tricyclic antidepressants (clomipramine, pipofezine) (20.0%), serotonin–norepinephrine reuptake inhibitors (duloxetine, venlafaxine) (7.1%), noradrenergic and specific serotonergic antidepressants (mirtazapine, mianserin) (2.7%), and agomelatine (12.3%). All antidepressants were used in recommended average therapeutic doses. The duration of treatment was not less than 28 days. For definition of remission, Hamilton Depression Rating scale 17 items (HDRS-17)<xref ref-type="bibr" rid="b50-pgpm-11-121">50</xref> was used. The evaluation was made on the 28th day of treatment. Remitters were identified if the HDRS-17 scores were ≤7.</p>
</sec>
<sec>
<title>Genotyping</title>
<p>Evacuated blood collection tubes “Vacutainer” (Becton Dickinson, Franklin Lakes, NJ, USA) with EDTA as the anticoagulant were used. Extraction of DNA from whole venous blood was performed using the phenol–chloroform method. Concentration and purity of DNA were measured using NanoDrop 8000 UV-Vis (ultraviolet-visible) spectrophotometer (Thermo Fisher Scientific, Waltham, MA, USA).</p>
<p>SNPs rs334558 of the <italic>GSK3B</italic> gene and rs1130214 and rs3730358 of the <italic>AKT1</italic> gene were genotyped by polymerase chain reaction (PCR) using the fluorogenic 5′-exonuclease TaqMan technology and the real-time PCR system “StepOne-Plus” (Applied Biosystems, Foster City, CA, USA).</p>
</sec>
<sec sec-type="methods">
<title>Statistical procedures</title>
<p>Statistical analyses were performed using SPSS software, V 20.0 (IBM Corporation, Armonk, NY, USA) for Windows. Pearson’s chi-square test was used for the between-group comparison of genotypic and allelic frequencies at significance level α = 0.05. Deviation from Hardy–Weinberg equilibrium of genotypic frequencies was also calculated with a chi-square test.</p>
</sec>
</sec>
<sec sec-type="results">
<title>Results</title>
<p>Of the three SNPs tested, none were associated with depressive disorders when genotypes and alleles were compared between cases and controls. Association was significant only for the SNP rs334558, constituted by alleles T and C, when the group of remitters was compared to non-remitters, for all pharmacological classes of medication taken together. Allele T was found to be associated with remission after 28 days of treatment. In particular, genotypes and alleles were different between remitters and non-remitters, at <italic>p</italic> = 0.049 and <italic>p</italic> = 0.015, respectively (odds ratio [OR] genotype T/T = 2.49, 95% CI: 0.98–6.30; OR allele T = 2.19, 95% confidence interval [CI]: 1.01–4.75). There was no deviation from Hardy–Weinberg equilibrium in the groups of remitters and non-remitters. <xref ref-type="table" rid="t1-pgpm-11-121">Table 1</xref> shows these results.</p>
<p>We also measured the association separately for the SSRI group, a class of medication used by the greatest proportion of patients in the cohort. Results of comparison between remitters and non-remitters, shown in <xref ref-type="table" rid="t2-pgpm-11-121">Table 2</xref>, were significant, at <italic>p</italic> = 0.039, only when alleles were compared, but not genotypes (OR genotype T/T = 3.05, 95% CI: 0.83–11.22; OR allele T = 2.37, 95% CI: 0.82–6.86). The same as for all classes of medication taken together, in the SSRI group remission was associated with allele T.</p>
</sec>
<sec sec-type="discussion">
<title>Discussion</title>
<p>Previous studies presented apparently conflicting results for rs334558, some reporting association of neurological and psychiatric phenotypes, such as Parkinson’s disease, Alzheimer’s disease, bipolar disorder, schizophrenia, adverse reaction to medication tardive dyskinesia, and resistance to treatment in the case of MDD and bipolar disorder, with the activating allele T,<xref ref-type="bibr" rid="b49-pgpm-11-121">49</xref>,<xref ref-type="bibr" rid="b51-pgpm-11-121">51</xref>–<xref ref-type="bibr" rid="b59-pgpm-11-121">59</xref> while others identified allele C as potentially pathogenic in the case of Alzheimer’s disease and multiple sclerosis.<xref ref-type="bibr" rid="b60-pgpm-11-121">60</xref>,<xref ref-type="bibr" rid="b61-pgpm-11-121">61</xref> Meta-analyses similarly reported either allele T associated with Alzheimer’s disease and MDD,<xref ref-type="bibr" rid="b62-pgpm-11-121">62</xref>,<xref ref-type="bibr" rid="b63-pgpm-11-121">63</xref> or allele C associated with schizophrenia.<xref ref-type="bibr" rid="b64-pgpm-11-121">64</xref></p>
<p>The present study reports association of remission following pharmacological antidepressant treatment with allele T of rs334558, but a previous study reported that this allele is associated with resistance to antidepressant medication<xref ref-type="bibr" rid="b53-pgpm-11-121">53</xref> and others reported association of this allele with poorer response to lithium treatment.<xref ref-type="bibr" rid="b54-pgpm-11-121">54</xref>–<xref ref-type="bibr" rid="b56-pgpm-11-121">56</xref> In all these studies, contribution of other molecular factors, including different genetic and epigenetic backgrounds, was not taken account of. Treatment-resistant depression is a phenomenon far from being fully understood, with multiple molecular factors likely contributing to its development.<xref ref-type="bibr" rid="b2-pgpm-11-121">2</xref>,<xref ref-type="bibr" rid="b65-pgpm-11-121">65</xref>,<xref ref-type="bibr" rid="b66-pgpm-11-121">66</xref> Different genetic and epigenetic backgrounds may modulate the influence of rs334558 on the response to drug treatment. In particular, the genetic landscape in different human populations could explain the changing direction of association depending on the population studied. In fact, allele frequencies of this functional variant change drastically in different human populations: according to data in the 1000 Genomes Project, the frequency of allele T goes from 67.1% in populations with European ancestry to 5.9% in populations with African ancestry (<ext-link ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/projects/SNP/snp_ss.cgi?ss=ss1305845106">https://www.ncbi.nlm.nih.gov/projects/SNP/snp_ss.cgi?ss=ss1305845106</ext-link>). This may mean that different genetic factors interact with this functional variant in different human populations. It is thus possible that in our cohort a different genetic and/or epigenetic background defines the different outcome in the presence of allele T, namely remission following pharmacological treatment. Further examples of extensively investigated functional candidate genes, whose association with mental disorders and treatment response changes in different populations, are the brain-derived neurotrophic factor, encoded by <italic>BDNF</italic>,<xref ref-type="bibr" rid="b67-pgpm-11-121">67</xref> and the serotonin transporter, encoded by <italic>SLC6A4</italic>.<xref ref-type="bibr" rid="b68-pgpm-11-121">68</xref></p>
<p>Because drug treatment of depressive disorders, due to their extensive heterogeneity, seems to be better viewed from the standpoint of personalized medicine, it is important to define actionable molecular biomarkers that will help predict treatment response.<xref ref-type="bibr" rid="b10-pgpm-11-121">10</xref>–<xref ref-type="bibr" rid="b19-pgpm-11-121">19</xref> The functional variant rs334558 could be such a genetic and pharmacogenetic biomarker for a number of phenotypes, including mood disorders, schizophrenia and neurodegenerative disorders. This biomarker could eventually be used in clinical settings, together with other relevant multidimensional data, such as levels of <italic>GSK3B</italic>’s promoter methylation or levels of expression of downstream targets of this gene, analyzed by machine-learning algorithms,<xref ref-type="bibr" rid="b69-pgpm-11-121">69</xref>–<xref ref-type="bibr" rid="b71-pgpm-11-121">71</xref> in order to determine the precise molecular etiopathological processes and recommend the appropriate personalized medicine-driven treatment.<xref ref-type="bibr" rid="b27-pgpm-11-121">27</xref>,<xref ref-type="bibr" rid="b72-pgpm-11-121">72</xref>–<xref ref-type="bibr" rid="b75-pgpm-11-121">75</xref></p>
<p>It is important to note that the personalized medicine approach, in the context of treatment of depressive disorders in particular, will be substantially complex because the task of determining actionable biomarkers will require an important volume of functional studies referring to treatment response. Multiplex functional studies<xref ref-type="bibr" rid="b76-pgpm-11-121">76</xref> should be the most appropriate way to proceed, given the substantial volume of data involved. In addition, personalized medicine applications in clinic, including pharmacogenetic testing, have not yet been convincingly shown to be cost-effective,<xref ref-type="bibr" rid="b73-pgpm-11-121">73</xref>,<xref ref-type="bibr" rid="b74-pgpm-11-121">74</xref> so more prospective studies evaluating cost-effectiveness and development of new cost-effective treatment schemes are needed.</p>
</sec>
<sec>
<title>Conclusion</title>
<p>This study reported data, suggesting the role of the functional variant rs334558 as a pharmacogenetic biomarker for depressive disorders in the context of personalized medicine-driven treatment. The results of genotyping should be used in conjunction with other relevant biomarkers because the phenotypic outcome in the case of this potential biomarker depends on other genetic and epigenetic factors that modulate it.</p>
</sec>
</body>
<back>
<ack>
<title>Acknowledgments</title>
<p>This work was in part accomplished within the framework of the Competitiveness Enhancement Program of Tomsk Polytechnic University, and was supported by the Russian Foundation for Basic Research, grant #17-29-02205.</p>
</ack>
<fn-group>
<fn fn-type="COI-statement">
<p>
<bold>Disclosure</bold>
</p>
<p>The authors report no conflicts of interest in this work.</p>
</fn>
</fn-group>
<ref-list>
<title>References</title>
<ref id="b1-pgpm-11-121">
<label>1</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<collab>GBD 2015 Disease and Injury Incidence and Prevalence Collaborators</collab>
</person-group>
<article-title>Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015</article-title>
<source/>Lancet
          <year>2016</year>
<volume>388</volume>
<issue>10053</issue>
<fpage>1545</fpage>
<lpage>1602</lpage>
<pub-id pub-id-type="pmid">27733282</pub-id>
</element-citation>
</ref>
<ref id="b2-pgpm-11-121">
<label>2</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Akil</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Gordon</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Hen</surname>
<given-names>R</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Treatment resistant depression: a multi-scale, systems biology approach</article-title>
<source/>Neurosci Biobehav Rev
          <year>2018</year>
<volume>84</volume>
<fpage>272</fpage>
<lpage>288</lpage>
<pub-id pub-id-type="pmid">28859997</pub-id>
</element-citation>
</ref>
<ref id="b3-pgpm-11-121">
<label>3</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Smoller</surname>
<given-names>JW</given-names>
</name>
</person-group>
<article-title>The genetics of stress-related disorders: PTSD, depression, and anxiety disorders</article-title>
<source/>Neuropsychopharmacology
          <year>2016</year>
<volume>41</volume>
<issue>1</issue>
<fpage>297</fpage>
<lpage>319</lpage>
<pub-id pub-id-type="pmid">26321314</pub-id>
</element-citation>
</ref>
<ref id="b4-pgpm-11-121">
<label>4</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mullins</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Lewis</surname>
<given-names>CM</given-names>
</name>
</person-group>
<article-title>Genetics of depression: progress at last</article-title>
<source/>Curr Psychiatry Rep
          <year>2017</year>
<volume>19</volume>
<issue>8</issue>
<fpage>43</fpage>
<pub-id pub-id-type="pmid">28608123</pub-id>
</element-citation>
</ref>
<ref id="b5-pgpm-11-121">
<label>5</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sullivan</surname>
<given-names>PF</given-names>
</name>
<name>
<surname>Daly</surname>
<given-names>MJ</given-names>
</name>
<name>
<surname>O’Donovan</surname>
<given-names>M</given-names>
</name>
</person-group>
<article-title>Genetic architectures of psychiatric disorders: the emerging picture and its implications</article-title>
<source/>Nat Rev Genet
          <year>2012</year>
<volume>13</volume>
<issue>8</issue>
<fpage>537</fpage>
<lpage>551</lpage>
<pub-id pub-id-type="pmid">22777127</pub-id>
</element-citation>
</ref>
<ref id="b6-pgpm-11-121">
<label>6</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kendler</surname>
<given-names>KS</given-names>
</name>
<name>
<surname>Gatz</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Gardner</surname>
<given-names>CO</given-names>
</name>
<name>
<surname>Pedersen</surname>
<given-names>NL</given-names>
</name>
</person-group>
<article-title>A Swedish national twin study of lifetime major depression</article-title>
<source/>Am J Psychiatry
          <year>2006</year>
<volume>163</volume>
<issue>1</issue>
<fpage>109</fpage>
<lpage>114</lpage>
<pub-id pub-id-type="pmid">16390897</pub-id>
</element-citation>
</ref>
<ref id="b7-pgpm-11-121">
<label>7</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sullivan</surname>
<given-names>PF</given-names>
</name>
<name>
<surname>Neale</surname>
<given-names>MC</given-names>
</name>
<name>
<surname>Kendler</surname>
<given-names>KS</given-names>
</name>
</person-group>
<article-title>Genetic epidemiology of major depression: review and meta-analysis</article-title>
<source/>Am J Psychiatry
          <year>2000</year>
<volume>157</volume>
<issue>10</issue>
<fpage>1552</fpage>
<lpage>1562</lpage>
<pub-id pub-id-type="pmid">11007705</pub-id>
</element-citation>
</ref>
<ref id="b8-pgpm-11-121">
<label>8</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pishva</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Rutten</surname>
<given-names>BPF</given-names>
</name>
<name>
<surname>van den Hove</surname>
<given-names>D</given-names>
</name>
</person-group>
<article-title>DNA methylation in major depressive disorder</article-title>
<source/>Adv Exp Med Biol
          <year>2017</year>
<volume>978</volume>
<fpage>185</fpage>
<lpage>196</lpage>
<pub-id pub-id-type="pmid">28523547</pub-id>
</element-citation>
</ref>
<ref id="b9-pgpm-11-121">
<label>9</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Deussing</surname>
<given-names>JM</given-names>
</name>
<name>
<surname>Jakovcevski</surname>
<given-names>M</given-names>
</name>
</person-group>
<article-title>Histone modifications in major depressive disorder and related rodent models</article-title>
<source/>Adv Exp Med Biol
          <year>2017</year>
<volume>978</volume>
<fpage>169</fpage>
<lpage>183</lpage>
<pub-id pub-id-type="pmid">28523546</pub-id>
</element-citation>
</ref>
<ref id="b10-pgpm-11-121">
<label>10</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Redei</surname>
<given-names>EE</given-names>
</name>
<name>
<surname>Mehta</surname>
<given-names>NS</given-names>
</name>
</person-group>
<article-title>The promise of biomarkers in diagnosing major depression in primary care: the present and future</article-title>
<source/>Curr Psychiatry Rep
          <year>2015</year>
<volume>17</volume>
<issue>8</issue>
<fpage>601</fpage>
<pub-id pub-id-type="pmid">26081681</pub-id>
</element-citation>
</ref>
<ref id="b11-pgpm-11-121">
<label>11</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Huang</surname>
<given-names>TL</given-names>
</name>
<name>
<surname>Lin</surname>
<given-names>CC</given-names>
</name>
</person-group>
<article-title>Advances in biomarkers of major depressive disorder</article-title>
<source/>Adv Clin Chem
          <year>2015</year>
<volume>68</volume>
<fpage>177</fpage>
<lpage>204</lpage>
<pub-id pub-id-type="pmid">25858873</pub-id>
</element-citation>
</ref>
<ref id="b12-pgpm-11-121">
<label>12</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Alhajji</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Nemeroff</surname>
<given-names>CB</given-names>
</name>
</person-group>
<article-title>Personalized medicine and mood disorders</article-title>
<source/>Psychiatr Clin North Am
          <year>2015</year>
<volume>38</volume>
<issue>3</issue>
<fpage>395</fpage>
<lpage>403</lpage>
<pub-id pub-id-type="pmid">26300030</pub-id>
</element-citation>
</ref>
<ref id="b13-pgpm-11-121">
<label>13</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fabbri</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Hosak</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Mossner</surname>
<given-names>R</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Consensus paper of the WFSBP Task Force on Genetics: genetics, epigenetics and gene expression markers of major depressive disorder and antidepressant response</article-title>
<source/>World J Biol Psychiatry
          <year>2017</year>
<volume>18</volume>
<issue>1</issue>
<fpage>5</fpage>
<lpage>28</lpage>
<pub-id pub-id-type="pmid">27603714</pub-id>
</element-citation>
</ref>
<ref id="b14-pgpm-11-121">
<label>14</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Smoller</surname>
<given-names>JW</given-names>
</name>
</person-group>
<article-title>Psychiatric genetics and the future of personalized treatment</article-title>
<source/>Depress Anxiety
          <year>2014</year>
<volume>31</volume>
<issue>11</issue>
<fpage>893</fpage>
<lpage>898</lpage>
<pub-id pub-id-type="pmid">25407575</pub-id>
</element-citation>
</ref>
<ref id="b15-pgpm-11-121">
<label>15</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Alda</surname>
<given-names>M</given-names>
</name>
</person-group>
<article-title>Personalized psychiatry: many questions, fewer answers</article-title>
<source/>J Psychiatry Neurosci
          <year>2013</year>
<volume>38</volume>
<issue>6</issue>
<fpage>363</fpage>
<lpage>365</lpage>
<pub-id pub-id-type="pmid">24148844</pub-id>
</element-citation>
</ref>
<ref id="b16-pgpm-11-121">
<label>16</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ozomaro</surname>
<given-names>U</given-names>
</name>
<name>
<surname>Wahlestedt</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Nemeroff</surname>
<given-names>CB</given-names>
</name>
</person-group>
<article-title>Personalized medicine in psychiatry: problems and promises</article-title>
<source/>BMC Med
          <year>2013</year>
<volume>11</volume>
<fpage>132</fpage>
<pub-id pub-id-type="pmid">23680237</pub-id>
</element-citation>
</ref>
<ref id="b17-pgpm-11-121">
<label>17</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wium-Andersen</surname>
<given-names>IK</given-names>
</name>
<name>
<surname>Vinberg</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Kessing</surname>
<given-names>LV</given-names>
</name>
<name>
<surname>McIntyre</surname>
<given-names>RS</given-names>
</name>
</person-group>
<article-title>Personalized medicine in psychiatry</article-title>
<source/>Nord J Psychiatry
          <year>2017</year>
<volume>71</volume>
<issue>1</issue>
<fpage>12</fpage>
<lpage>19</lpage>
<pub-id pub-id-type="pmid">27564242</pub-id>
</element-citation>
</ref>
<ref id="b18-pgpm-11-121">
<label>18</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Demkow</surname>
<given-names>U</given-names>
</name>
<name>
<surname>Wolanczyk</surname>
<given-names>T</given-names>
</name>
</person-group>
<article-title>Genetic tests in major psychiatric disorders-integrating molecular medicine with clinical psychiatry-why is it so difficult?</article-title>
<source/>Transl Psychiatry
          <year>2017</year>
<volume>7</volume>
<issue>6</issue>
<fpage>e1151</fpage>
<pub-id pub-id-type="pmid">28608853</pub-id>
</element-citation>
</ref>
<ref id="b19-pgpm-11-121">
<label>19</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Loonen</surname>
<given-names>AJ</given-names>
</name>
<name>
<surname>Stahl</surname>
<given-names>SM</given-names>
</name>
</person-group>
<article-title>Functional psychopharmacology is the way to go in pharmacotherapy for psychiatric disorders</article-title>
<source/>Acta Psychiatr Scand
          <year>2010</year>
<volume>122</volume>
<issue>6</issue>
<fpage>435</fpage>
<lpage>437</lpage>
<pub-id pub-id-type="pmid">21054280</pub-id>
</element-citation>
</ref>
<ref id="b20-pgpm-11-121">
<label>20</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cuthbert</surname>
<given-names>BN</given-names>
</name>
</person-group>
<article-title>Research domain criteria: toward future psychiatric nosologies</article-title>
<source/>Dialogues Clin Neurosci
          <year>2015</year>
<volume>17</volume>
<issue>1</issue>
<fpage>89</fpage>
<lpage>97</lpage>
<pub-id pub-id-type="pmid">25987867</pub-id>
</element-citation>
</ref>
<ref id="b21-pgpm-11-121">
<label>21</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Morris</surname>
<given-names>SE</given-names>
</name>
<name>
<surname>Cuthbert</surname>
<given-names>BN</given-names>
</name>
</person-group>
<article-title>Research domain criteria: cognitive systems, neural circuits, and dimensions of behavior</article-title>
<source/>Dialogues Clin Neurosci
          <year>2012</year>
<volume>14</volume>
<issue>1</issue>
<fpage>29</fpage>
<lpage>37</lpage>
<pub-id pub-id-type="pmid">22577302</pub-id>
</element-citation>
</ref>
<ref id="b22-pgpm-11-121">
<label>22</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Insel</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Cuthbert</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Garvey</surname>
<given-names>M</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Research domain criteria (RDoC): toward a new classification framework for research on mental disorders</article-title>
<source/>Am J Psychiatry
          <year>2010</year>
<volume>167</volume>
<issue>7</issue>
<fpage>748</fpage>
<lpage>751</lpage>
<pub-id pub-id-type="pmid">20595427</pub-id>
</element-citation>
</ref>
<ref id="b23-pgpm-11-121">
<label>23</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Thase</surname>
<given-names>ME</given-names>
</name>
<name>
<surname>Schwartz</surname>
<given-names>TL</given-names>
</name>
</person-group>
<article-title>Choosing medications for treatment-resistant depression based on mechanism of action</article-title>
<source/>J Clin Psychiatry
          <year>2015</year>
<volume>76</volume>
<issue>6</issue>
<fpage>720</fpage>
<lpage>727</lpage>
<comment>quiz 727</comment>
<pub-id pub-id-type="pmid">26132673</pub-id>
</element-citation>
</ref>
<ref id="b24-pgpm-11-121">
<label>24</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lin</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Lane</surname>
<given-names>HY</given-names>
</name>
</person-group>
<article-title>Genome-wide association studies in pharmacogenomics of antidepressants</article-title>
<source/>Pharmacogenomics
          <year>2015</year>
<volume>16</volume>
<issue>5</issue>
<fpage>555</fpage>
<lpage>566</lpage>
<pub-id pub-id-type="pmid">25916525</pub-id>
</element-citation>
</ref>
<ref id="b25-pgpm-11-121">
<label>25</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fabbri</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Serretti</surname>
<given-names>A</given-names>
</name>
</person-group>
<article-title>Pharmacogenetics of major depressive disorder: top genes and pathways toward clinical applications</article-title>
<source/>Curr Psychiatry Rep
          <year>2015</year>
<volume>17</volume>
<issue>7</issue>
<fpage>50</fpage>
<pub-id pub-id-type="pmid">25980509</pub-id>
</element-citation>
</ref>
<ref id="b26-pgpm-11-121">
<label>26</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fabbri</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Crisafulli</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Calabro</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Spina</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Serretti</surname>
<given-names>A</given-names>
</name>
</person-group>
<article-title>Progress and prospects in pharmacogenetics of antidepressant drugs</article-title>
<source/>Expert Opin Drug Metab Toxicol
          <year>2016</year>
<volume>12</volume>
<issue>10</issue>
<fpage>1157</fpage>
<lpage>1168</lpage>
<pub-id pub-id-type="pmid">27310483</pub-id>
</element-citation>
</ref>
<ref id="b27-pgpm-11-121">
<label>27</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ramos</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Berrogain</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Concha</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Lomba</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Garcia</surname>
<given-names>CB</given-names>
</name>
<name>
<surname>Ribate</surname>
<given-names>MP</given-names>
</name>
</person-group>
<article-title>Pharmacogenetic studies: a tool to improve antidepressant therapy</article-title>
<source/>Drug Metab Pers Ther
          <year>2016</year>
<volume>31</volume>
<issue>4</issue>
<fpage>197</fpage>
<lpage>204</lpage>
<pub-id pub-id-type="pmid">27889704</pub-id>
</element-citation>
</ref>
<ref id="b28-pgpm-11-121">
<label>28</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Losenkov</surname>
<given-names>IS</given-names>
</name>
<name>
<surname>Vyalova</surname>
<given-names>NM</given-names>
</name>
<name>
<surname>Simutkin</surname>
<given-names>GG</given-names>
</name>
<name>
<surname>Bokhan</surname>
<given-names>NA</given-names>
</name>
<name>
<surname>Ivanova</surname>
<given-names>SA</given-names>
</name>
</person-group>
<article-title>An association of <italic>AKT1 g</italic>ene polymorphism with antidepressant treatment response</article-title>
<source/>World J Biol Psychiatry
          <year>2016</year>
<volume>17</volume>
<issue>3</issue>
<fpage>239</fpage>
<lpage>242</lpage>
<pub-id pub-id-type="pmid">26515520</pub-id>
</element-citation>
</ref>
<ref id="b29-pgpm-11-121">
<label>29</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lisoway</surname>
<given-names>AJ</given-names>
</name>
<name>
<surname>Zai</surname>
<given-names>CC</given-names>
</name>
<name>
<surname>Tiwari</surname>
<given-names>AK</given-names>
</name>
<name>
<surname>Kennedy</surname>
<given-names>JL</given-names>
</name>
</person-group>
<article-title>DNA methylation and clinical response to antidepressant medication in major depressive disorder: a review and recommendations</article-title>
<source/>Neurosci Lett
          <year>2018</year>
<volume>669</volume>
<fpage>14</fpage>
<lpage>23</lpage>
<pub-id pub-id-type="pmid">28063933</pub-id>
</element-citation>
</ref>
<ref id="b30-pgpm-11-121">
<label>30</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Beaulieu</surname>
<given-names>JM</given-names>
</name>
<name>
<surname>Gainetdinov</surname>
<given-names>RR</given-names>
</name>
<name>
<surname>Caron</surname>
<given-names>MG</given-names>
</name>
</person-group>
<article-title><italic>Akt/GSK3</italic> signaling in the action of psychotropic drugs</article-title>
<source/>Annu Rev Pharmacol Toxicol
          <year>2009</year>
<volume>49</volume>
<fpage>327</fpage>
<lpage>347</lpage>
<pub-id pub-id-type="pmid">18928402</pub-id>
</element-citation>
</ref>
<ref id="b31-pgpm-11-121">
<label>31</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Freyberg</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>Ferrando</surname>
<given-names>SJ</given-names>
</name>
<name>
<surname>Javitch</surname>
<given-names>JA</given-names>
</name>
</person-group>
<article-title>Roles of the <italic>Akt/GSK-3</italic> and Wnt signaling pathways in schizophrenia and antipsychotic drug action</article-title>
<source/>Am J Psychiatry
          <year>2010</year>
<volume>167</volume>
<issue>4</issue>
<fpage>388</fpage>
<lpage>396</lpage>
<pub-id pub-id-type="pmid">19917593</pub-id>
</element-citation>
</ref>
<ref id="b32-pgpm-11-121">
<label>32</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Emamian</surname>
<given-names>ES</given-names>
</name>
</person-group>
<article-title><italic>AKT/GSK3</italic> signaling pathway and schizophrenia</article-title>
<source/>Front Mol Neurosci
          <year>2012</year>
<volume>5</volume>
<fpage>33</fpage>
<pub-id pub-id-type="pmid">22435049</pub-id>
</element-citation>
</ref>
<ref id="b33-pgpm-11-121">
<label>33</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Losenkov</surname>
<given-names>IS</given-names>
</name>
<name>
<surname>Ivanova</surname>
<given-names>SA</given-names>
</name>
<name>
<surname>Vyalova</surname>
<given-names>NA</given-names>
</name>
<name>
<surname>Simutkin</surname>
<given-names>GG</given-names>
</name>
<name>
<surname>Bokhan</surname>
<given-names>NA</given-names>
</name>
</person-group>
<article-title>Proteins of the <italic>Akt1/GSK-3b</italic> signaling pathway in peripheral blood mononuclear cells of patients with affective disorders</article-title>
<source/>Neurochem J
          <year>2014</year>
<volume>8</volume>
<issue>3</issue>
<fpage>208</fpage>
<lpage>213</lpage>
</element-citation>
</ref>
<ref id="b34-pgpm-11-121">
<label>34</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Emamian</surname>
<given-names>ES</given-names>
</name>
<name>
<surname>Hall</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Birnbaum</surname>
<given-names>MJ</given-names>
</name>
<name>
<surname>Karayiorgou</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Gogos</surname>
<given-names>JA</given-names>
</name>
</person-group>
<article-title>Convergent evidence for impaired <italic>AKT1-GSK3</italic>beta signaling in schizophrenia</article-title>
<source/>Nat Genet
          <year>2004</year>
<volume>36</volume>
<issue>2</issue>
<fpage>131</fpage>
<lpage>137</lpage>
<pub-id pub-id-type="pmid">14745448</pub-id>
</element-citation>
</ref>
<ref id="b35-pgpm-11-121">
<label>35</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pereira</surname>
<given-names>PA</given-names>
</name>
<name>
<surname>Bicalho</surname>
<given-names>MA</given-names>
</name>
<name>
<surname>de Moraes</surname>
<given-names>EN</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Genetic variant of <italic>AKT1</italic> and <italic>AKTIP</italic> associated with late-onset depression in a Brazilian population</article-title>
<source/>Int J Geriatr Psychiatry
          <year>2014</year>
<volume>29</volume>
<issue>4</issue>
<fpage>399</fpage>
<lpage>405</lpage>
<pub-id pub-id-type="pmid">24022875</pub-id>
</element-citation>
</ref>
<ref id="b36-pgpm-11-121">
<label>36</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Doble</surname>
<given-names>BW</given-names>
</name>
<name>
<surname>Woodgett</surname>
<given-names>JR</given-names>
</name>
</person-group>
<article-title><italic>GSK-3</italic>: tricks of the trade for a multi-tasking kinase</article-title>
<source/>J Cell Sci
          <year>2003</year>
<volume>116</volume>
<issue>Pt 7</issue>
<fpage>1175</fpage>
<lpage>1186</lpage>
<pub-id pub-id-type="pmid">12615961</pub-id>
</element-citation>
</ref>
<ref id="b37-pgpm-11-121">
<label>37</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Logan</surname>
<given-names>CY</given-names>
</name>
<name>
<surname>Nusse</surname>
<given-names>R</given-names>
</name>
</person-group>
<article-title>The Wnt signaling pathway in development and disease</article-title>
<source/>Annu Rev Cell Dev Biol
          <year>2004</year>
<volume>20</volume>
<fpage>781</fpage>
<lpage>810</lpage>
<pub-id pub-id-type="pmid">15473860</pub-id>
</element-citation>
</ref>
<ref id="b38-pgpm-11-121">
<label>38</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lovestone</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Killick</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Di Forti</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Murray</surname>
<given-names>R</given-names>
</name>
</person-group>
<article-title>Schizophrenia as a <italic>GSK-3</italic> dysregulation disorder</article-title>
<source/>Trends Neurosci
          <year>2007</year>
<volume>30</volume>
<issue>4</issue>
<fpage>142</fpage>
<lpage>149</lpage>
<pub-id pub-id-type="pmid">17324475</pub-id>
</element-citation>
</ref>
<ref id="b39-pgpm-11-121">
<label>39</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Li</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Jope</surname>
<given-names>RS</given-names>
</name>
</person-group>
<article-title>Is glycogen synthase kinase-3 a central modulator in mood regulation?</article-title>
<source/>Neuropsychopharmacology
          <year>2010</year>
<volume>35</volume>
<issue>11</issue>
<fpage>2143</fpage>
<lpage>2154</lpage>
<pub-id pub-id-type="pmid">20668436</pub-id>
</element-citation>
</ref>
<ref id="b40-pgpm-11-121">
<label>40</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Singh</surname>
<given-names>KK</given-names>
</name>
</person-group>
<article-title>An emerging role for Wnt and GSK3 signaling pathways in schizophrenia</article-title>
<source/>Clin Genet
          <year>2013</year>
<volume>83</volume>
<issue>6</issue>
<fpage>511</fpage>
<lpage>517</lpage>
<pub-id pub-id-type="pmid">23379509</pub-id>
</element-citation>
</ref>
<ref id="b41-pgpm-11-121">
<label>41</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dachtler</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Elliott</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Rodgers</surname>
<given-names>RJ</given-names>
</name>
<name>
<surname>Baillie</surname>
<given-names>GS</given-names>
</name>
<name>
<surname>Clapcote</surname>
<given-names>SJ</given-names>
</name>
</person-group>
<article-title>Missense mutation in DISC1 C-terminal coiled-coil has <italic>GSK3</italic>beta signaling and sex-dependent behavioral effects in mice</article-title>
<source/>Sci Rep
          <year>2016</year>
<volume>6</volume>
<fpage>18748</fpage>
<pub-id pub-id-type="pmid">26728762</pub-id>
</element-citation>
</ref>
<ref id="b42-pgpm-11-121">
<label>42</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Levchenko</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Davtian</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Freylichman</surname>
<given-names>O</given-names>
</name>
<name>
<surname>Zagrivnaya</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Kostareva</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Malashichev</surname>
<given-names>Y</given-names>
</name>
</person-group>
<article-title>Beta-catenin in schizophrenia: possibly deleterious novel mutation</article-title>
<source/>Psychiatry Res
          <year>2015</year>
<volume>228</volume>
<issue>3</issue>
<fpage>843</fpage>
<lpage>848</lpage>
<pub-id pub-id-type="pmid">26027441</pub-id>
</element-citation>
</ref>
<ref id="b43-pgpm-11-121">
<label>43</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>de Ligt</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Willemsen</surname>
<given-names>MH</given-names>
</name>
<name>
<surname>van Bon</surname>
<given-names>BW</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Diagnostic exome sequencing in persons with severe intellectual disability</article-title>
<source/>N Engl J Med
          <year>2012</year>
<volume>367</volume>
<issue>20</issue>
<fpage>1921</fpage>
<lpage>1929</lpage>
<pub-id pub-id-type="pmid">23033978</pub-id>
</element-citation>
</ref>
<ref id="b44-pgpm-11-121">
<label>44</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kharbanda</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Pilz</surname>
<given-names>DT</given-names>
</name>
<name>
<surname>Tomkins</surname>
<given-names>S</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Clinical features associated with CTNNB1 de novo loss of function mutations in ten individuals</article-title>
<source/>Eur J Med Genet
          <year>2017</year>
<volume>60</volume>
<issue>2</issue>
<fpage>130</fpage>
<lpage>135</lpage>
<pub-id pub-id-type="pmid">27915094</pub-id>
</element-citation>
</ref>
<ref id="b45-pgpm-11-121">
<label>45</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Li</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Xu</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>G</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Exome sequencing identifies a de novo mutation of CTNNB1 gene in a patient mainly presented with retinal detachment, lens and vitreous opacities, microcephaly, and developmental delay: case report and literature review</article-title>
<source/>Medicine (Baltimore)
          <year>2017</year>
<volume>96</volume>
<issue>20</issue>
<fpage>e6914</fpage>
<pub-id pub-id-type="pmid">28514307</pub-id>
</element-citation>
</ref>
<ref id="b46-pgpm-11-121">
<label>46</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>O’Roak</surname>
<given-names>BJ</given-names>
</name>
<name>
<surname>Vives</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Girirajan</surname>
<given-names>S</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Sporadic autism exomes reveal a highly interconnected protein network of de novo mutations</article-title>
<source/>Nature
          <year>2012</year>
<volume>485</volume>
<issue>7397</issue>
<fpage>246</fpage>
<lpage>250</lpage>
<pub-id pub-id-type="pmid">22495309</pub-id>
</element-citation>
</ref>
<ref id="b47-pgpm-11-121">
<label>47</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tucci</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Kleefstra</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Hardy</surname>
<given-names>A</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Dominant beta-catenin mutations cause intellectual disability with recognizable syndromic features</article-title>
<source/>J Clin Invest
          <year>2014</year>
<volume>124</volume>
<issue>4</issue>
<fpage>1468</fpage>
<lpage>1482</lpage>
<pub-id pub-id-type="pmid">24614104</pub-id>
</element-citation>
</ref>
<ref id="b48-pgpm-11-121">
<label>48</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mao</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Ge</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Frank</surname>
<given-names>CL</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Disrupted in schizophrenia 1 regulates neuronal progenitor proliferation via modulation of <italic>GSK3</italic>beta/betacatenin signaling</article-title>
<source/>Cell
          <year>2009</year>
<volume>136</volume>
<issue>6</issue>
<fpage>1017</fpage>
<lpage>1031</lpage>
<pub-id pub-id-type="pmid">19303846</pub-id>
</element-citation>
</ref>
<ref id="b49-pgpm-11-121">
<label>49</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kwok</surname>
<given-names>JB</given-names>
</name>
<name>
<surname>Hallupp</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Loy</surname>
<given-names>CT</given-names>
</name>
<etal></etal>
</person-group>
<article-title><italic>GSK3</italic>B polymorphisms alter transcription and splicing in Parkinson’s disease</article-title>
<source/>Ann Neurol
          <year>2005</year>
<volume>58</volume>
<issue>6</issue>
<fpage>829</fpage>
<lpage>839</lpage>
<pub-id pub-id-type="pmid">16315267</pub-id>
</element-citation>
</ref>
<ref id="b50-pgpm-11-121">
<label>50</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hamilton</surname>
<given-names>M</given-names>
</name>
</person-group>
<article-title>A rating scale for depression</article-title>
<source/>J Neurol Neurosurg Psychiatry
          <year>1960</year>
<volume>23</volume>
<fpage>56</fpage>
<lpage>62</lpage>
<pub-id pub-id-type="pmid">14399272</pub-id>
</element-citation>
</ref>
<ref id="b51-pgpm-11-121">
<label>51</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mateo</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Vazquez-Higuera</surname>
<given-names>JL</given-names>
</name>
<name>
<surname>Sanchez-Juan</surname>
<given-names>P</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Epistasis between tau phosphorylation regulating genes (CDK5R1 and <italic>GSK</italic>-3beta) and Alzheimer’s disease risk</article-title>
<source/>Acta Neurol Scand
          <year>2009</year>
<volume>120</volume>
<issue>2</issue>
<fpage>130</fpage>
<lpage>133</lpage>
<pub-id pub-id-type="pmid">19154537</pub-id>
</element-citation>
</ref>
<ref id="b52-pgpm-11-121">
<label>52</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Park</surname>
<given-names>SW</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>JG</given-names>
</name>
<name>
<surname>Kong</surname>
<given-names>BG</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Genetic association of <italic>BDNF</italic> val-66met and <italic>GSK</italic>-3beta-50T/C polymorphisms with tardive dyskinesia</article-title>
<source/>Psychiatry Clin Neurosci
          <year>2009</year>
<volume>63</volume>
<issue>4</issue>
<fpage>433</fpage>
<lpage>439</lpage>
<pub-id pub-id-type="pmid">19457211</pub-id>
</element-citation>
</ref>
<ref id="b53-pgpm-11-121">
<label>53</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tsai</surname>
<given-names>SJ</given-names>
</name>
<name>
<surname>Liou</surname>
<given-names>YJ</given-names>
</name>
<name>
<surname>Hong</surname>
<given-names>CJ</given-names>
</name>
<name>
<surname>Yu</surname>
<given-names>YW</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>TJ</given-names>
</name>
</person-group>
<article-title>Glycogen synthase kinase-3beta gene is associated with antidepressant treatment response in Chinese major depressive disorder</article-title>
<source/>Pharmacogenomics J
          <year>2008</year>
<volume>8</volume>
<issue>6</issue>
<fpage>384</fpage>
<lpage>390</lpage>
<pub-id pub-id-type="pmid">18195729</pub-id>
</element-citation>
</ref>
<ref id="b54-pgpm-11-121">
<label>54</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Benedetti</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Bollettini</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Barberi</surname>
<given-names>I</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Lithium and <italic>GSK3</italic>-beta promoter gene variants influence white matter microstructure in bipolar disorder</article-title>
<source/>Neuropsychopharmacology
          <year>2013</year>
<volume>38</volume>
<issue>2</issue>
<fpage>313</fpage>
<lpage>327</lpage>
<pub-id pub-id-type="pmid">22990942</pub-id>
</element-citation>
</ref>
<ref id="b55-pgpm-11-121">
<label>55</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lin</surname>
<given-names>YF</given-names>
</name>
<name>
<surname>Huang</surname>
<given-names>MC</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>HC</given-names>
</name>
</person-group>
<article-title>Glycogen synthase kinase 3beta gene polymorphisms may be associated with bipolar I disorder and the therapeutic response to lithium</article-title>
<source/>J Affect Disord
          <year>2013</year>
<volume>147</volume>
<issue>1–3</issue>
<fpage>401</fpage>
<lpage>406</lpage>
<pub-id pub-id-type="pmid">23021822</pub-id>
</element-citation>
</ref>
<ref id="b56-pgpm-11-121">
<label>56</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Benedetti</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Poletti</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Radaelli</surname>
<given-names>D</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Lithium and <italic>GSK-3</italic>beta promoter gene variants influence cortical gray matter volumes in bipolar disorder</article-title>
<source/>Psychopharmacology (Berl)
          <year>2015</year>
<volume>232</volume>
<issue>7</issue>
<fpage>1325</fpage>
<lpage>1336</lpage>
<pub-id pub-id-type="pmid">25345732</pub-id>
</element-citation>
</ref>
<ref id="b57-pgpm-11-121">
<label>57</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Benedetti</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Poletti</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Radaelli</surname>
<given-names>D</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Temporal lobe grey matter volume in schizophrenia is associated with a genetic polymorphism influencing glycogen synthase kinase 3-beta activity</article-title>
<source/>Genes Brain Behav
          <year>2010</year>
<volume>9</volume>
<issue>4</issue>
<fpage>365</fpage>
<lpage>371</lpage>
<pub-id pub-id-type="pmid">20113358</pub-id>
</element-citation>
</ref>
<ref id="b58-pgpm-11-121">
<label>58</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Benedetti</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Bernasconi</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Lorenzi</surname>
<given-names>C</given-names>
</name>
<etal></etal>
</person-group>
<article-title>A single nucleotide polymorphism in glycogen synthase kinase 3-beta promoter gene influences onset of illness in patients affected by bipolar disorder</article-title>
<source/>Neurosci Lett
          <year>2004</year>
<volume>355</volume>
<issue>1–2</issue>
<fpage>37</fpage>
<lpage>40</lpage>
<pub-id pub-id-type="pmid">14729229</pub-id>
</element-citation>
</ref>
<ref id="b59-pgpm-11-121">
<label>59</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Benedetti</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Serretti</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Colombo</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Lorenzi</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Tubazio</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Smeraldi</surname>
<given-names>E</given-names>
</name>
</person-group>
<article-title>A glycogen synthase kinase 3-beta promoter gene single nucleotide polymorphism is associated with age at onset and response to total sleep deprivation in bipolar depression</article-title>
<source/>Neurosci Lett
          <year>2004</year>
<volume>368</volume>
<issue>2</issue>
<fpage>123</fpage>
<lpage>126</lpage>
<pub-id pub-id-type="pmid">15351432</pub-id>
</element-citation>
</ref>
<ref id="b60-pgpm-11-121">
<label>60</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kettunen</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Larsson</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Holmgren</surname>
<given-names>S</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Genetic variants of <italic>GSK3</italic>B are associated with biomarkers for Alzheimer’s disease and cognitive function</article-title>
<source/>J Alzheimers Dis
          <year>2015</year>
<volume>44</volume>
<issue>4</issue>
<fpage>1313</fpage>
<lpage>1322</lpage>
<pub-id pub-id-type="pmid">25420549</pub-id>
</element-citation>
</ref>
<ref id="b61-pgpm-11-121">
<label>61</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Galimberti</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Macmurray</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Scalabrini</surname>
<given-names>D</given-names>
</name>
<etal></etal>
</person-group>
<article-title><italic>GSK3</italic>beta genetic variability in patients with multiple sclerosis</article-title>
<source/>Neurosci Lett
          <year>2011</year>
<volume>497</volume>
<issue>1</issue>
<fpage>46</fpage>
<lpage>48</lpage>
<pub-id pub-id-type="pmid">21527318</pub-id>
</element-citation>
</ref>
<ref id="b62-pgpm-11-121">
<label>62</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lin</surname>
<given-names>Q</given-names>
</name>
<name>
<surname>Cao</surname>
<given-names>YP</given-names>
</name>
<name>
<surname>Gao</surname>
<given-names>J</given-names>
</name>
</person-group>
<article-title>Common polymorphisms in the <italic>GSK3</italic>beta gene may contribute to the pathogenesis of Alzheimer disease: a meta-analysis</article-title>
<source/>J Geriatr Psychiatry Neurol
          <year>2015</year>
<volume>28</volume>
<issue>2</issue>
<fpage>83</fpage>
<lpage>93</lpage>
<pub-id pub-id-type="pmid">25351705</pub-id>
</element-citation>
</ref>
<ref id="b63-pgpm-11-121">
<label>63</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Liu</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Sun</surname>
<given-names>N</given-names>
</name>
<etal></etal>
</person-group>
<article-title>The gender-specific association of rs334558 in <italic>GSK3</italic>beta with major depressive disorder</article-title>
<source/>Medicine (Baltimore)
          <year>2017</year>
<volume>96</volume>
<issue>3</issue>
<fpage>e5928</fpage>
<pub-id pub-id-type="pmid">28099358</pub-id>
</element-citation>
</ref>
<ref id="b64-pgpm-11-121">
<label>64</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tang</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Shen</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Jin</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Miao</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Zhu</surname>
<given-names>LQ</given-names>
</name>
</person-group>
<article-title><italic>GSK-3</italic>beta polymorphism discriminates bipolar disorder and schizophrenia: a systematic meta-analysis</article-title>
<source/>Mol Neurobiol
          <year>2013</year>
<volume>48</volume>
<issue>3</issue>
<fpage>404</fpage>
<lpage>411</lpage>
<pub-id pub-id-type="pmid">23440732</pub-id>
</element-citation>
</ref>
<ref id="b65-pgpm-11-121">
<label>65</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kim</surname>
<given-names>YK</given-names>
</name>
<name>
<surname>Na</surname>
<given-names>KS</given-names>
</name>
</person-group>
<article-title>Role of glutamate receptors and glial cells in the pathophysiology of treatment-resistant depression</article-title>
<source/>Prog Neuropsychopharmacol Biol Psychiatry
          <year>2016</year>
<volume>70</volume>
<fpage>117</fpage>
<lpage>126</lpage>
<pub-id pub-id-type="pmid">27046518</pub-id>
</element-citation>
</ref>
<ref id="b66-pgpm-11-121">
<label>66</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kulikov</surname>
<given-names>AV</given-names>
</name>
<name>
<surname>Gainetdinov</surname>
<given-names>RR</given-names>
</name>
<name>
<surname>Ponimaskin</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Kalueff</surname>
<given-names>AV</given-names>
</name>
<name>
<surname>Naumenko</surname>
<given-names>VS</given-names>
</name>
<name>
<surname>Popova</surname>
<given-names>NK</given-names>
</name>
</person-group>
<article-title>Interplay between the key proteins of serotonin system in SSRI antidepressants efficacy</article-title>
<source/>Expert Opin Ther Targets
          <year>2018</year>
<volume>22</volume>
<issue>4</issue>
<fpage>319</fpage>
<lpage>330</lpage>
<pub-id pub-id-type="pmid">29542343</pub-id>
</element-citation>
</ref>
<ref id="b67-pgpm-11-121">
<label>67</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Notaras</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Hill</surname>
<given-names>R</given-names>
</name>
<name>
<surname>van den Buuse</surname>
<given-names>M</given-names>
</name>
</person-group>
<article-title>A role for the BDNF gene Val66Met polymorphism in schizophrenia? A comprehensive review</article-title>
<source/>Neurosci Biobehav Rev
          <year>2015</year>
<volume>51</volume>
<fpage>15</fpage>
<lpage>30</lpage>
<pub-id pub-id-type="pmid">25562189</pub-id>
</element-citation>
</ref>
<ref id="b68-pgpm-11-121">
<label>68</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mrazek</surname>
<given-names>DA</given-names>
</name>
<name>
<surname>Rush</surname>
<given-names>AJ</given-names>
</name>
<name>
<surname>Biernacka</surname>
<given-names>JM</given-names>
</name>
<etal></etal>
</person-group>
<article-title>SLC6A4 variation and citalopram response</article-title>
<source/>Am J Med Genet B Neuropsychiatr Genet
          <year>2009</year>
<volume>150B</volume>
<issue>3</issue>
<fpage>341</fpage>
<lpage>351</lpage>
<pub-id pub-id-type="pmid">18618621</pub-id>
</element-citation>
</ref>
<ref id="b69-pgpm-11-121">
<label>69</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Adams</surname>
<given-names>RA</given-names>
</name>
<name>
<surname>Huys</surname>
<given-names>QJ</given-names>
</name>
<name>
<surname>Roiser</surname>
<given-names>JP</given-names>
</name>
</person-group>
<article-title>Computational psychiatry: towards a mathematically informed understanding of mental illness</article-title>
<source/>J Neurol Neurosurg Psychiatry
          <year>2016</year>
<volume>87</volume>
<issue>1</issue>
<fpage>53</fpage>
<lpage>63</lpage>
<pub-id pub-id-type="pmid">26157034</pub-id>
</element-citation>
</ref>
<ref id="b70-pgpm-11-121">
<label>70</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hahn</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Nierenberg</surname>
<given-names>AA</given-names>
</name>
<name>
<surname>Whitfield-Gabrieli</surname>
<given-names>S</given-names>
</name>
</person-group>
<article-title>Predictive analytics in mental health: applications, guidelines, challenges and perspectives</article-title>
<source/>Mol Psychiatry
          <year>2017</year>
<volume>22</volume>
<issue>1</issue>
<fpage>37</fpage>
<lpage>43</lpage>
<pub-id pub-id-type="pmid">27843153</pub-id>
</element-citation>
</ref>
<ref id="b71-pgpm-11-121">
<label>71</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Huys</surname>
<given-names>QJ</given-names>
</name>
<name>
<surname>Maia</surname>
<given-names>TV</given-names>
</name>
<name>
<surname>Frank</surname>
<given-names>MJ</given-names>
</name>
</person-group>
<article-title>Computational psychiatry as a bridge from neuroscience to clinical applications</article-title>
<source/>Nat Neurosci
          <year>2016</year>
<volume>19</volume>
<issue>3</issue>
<fpage>404</fpage>
<lpage>413</lpage>
<pub-id pub-id-type="pmid">26906507</pub-id>
</element-citation>
</ref>
<ref id="b72-pgpm-11-121">
<label>72</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nassan</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Nicholson</surname>
<given-names>WT</given-names>
</name>
<name>
<surname>Elliott</surname>
<given-names>MA</given-names>
</name>
<name>
<surname>Rohrer Vitek</surname>
<given-names>CR</given-names>
</name>
<name>
<surname>Black</surname>
<given-names>JL</given-names>
</name>
<name>
<surname>Frye</surname>
<given-names>MA</given-names>
</name>
</person-group>
<article-title>Pharmacokinetic pharmacogenetic prescribing guidelines for antidepressants: a template for psychiatric precision medicine</article-title>
<source/>Mayo Clin Proc
          <year>2016</year>
<volume>91</volume>
<issue>7</issue>
<fpage>897</fpage>
<lpage>907</lpage>
<pub-id pub-id-type="pmid">27289413</pub-id>
</element-citation>
</ref>
<ref id="b73-pgpm-11-121">
<label>73</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rosenblat</surname>
<given-names>JD</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>McIntyre</surname>
<given-names>RS</given-names>
</name>
</person-group>
<article-title>Does pharmacogenomic testing improve clinical outcomes for major depressive disorder? A systematic review of clinical trials and cost-effectiveness studies</article-title>
<source/>J Clin Psychiatry
          <year>2017</year>
<volume>78</volume>
<issue>6</issue>
<fpage>720</fpage>
<lpage>729</lpage>
<pub-id pub-id-type="pmid">28068459</pub-id>
</element-citation>
</ref>
<ref id="b74-pgpm-11-121">
<label>74</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Peterson</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Dieperink</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Anderson</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Boundy</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Ferguson</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Helfand</surname>
<given-names>M</given-names>
</name>
</person-group>
<article-title>Rapid evidence review of the comparative effectiveness, harms, and cost-effectiveness of pharmacogenomics-guided antidepressant treatment versus usual care for major depressive disorder</article-title>
<source/>Psychophar-macology (Berl)
          <year>2017</year>
<volume>234</volume>
<issue>11</issue>
<fpage>1649</fpage>
<lpage>1661</lpage>
</element-citation>
</ref>
<ref id="b75-pgpm-11-121">
<label>75</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Madan</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Walker</surname>
<given-names>CR</given-names>
</name>
<name>
<surname>Weinstein</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Fowler</surname>
<given-names>JC</given-names>
</name>
</person-group>
<article-title>Pharmacogenomics in practice: a case report of personalized inpatient psychiatric care</article-title>
<source/>Pharmacogenomics
          <year>2015</year>
<volume>16</volume>
<issue>5</issue>
<fpage>433</fpage>
<lpage>439</lpage>
<pub-id pub-id-type="pmid">25916515</pub-id>
</element-citation>
</ref>
<ref id="b76-pgpm-11-121">
<label>76</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Starita</surname>
<given-names>LM</given-names>
</name>
<name>
<surname>Ahituv</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Dunham</surname>
<given-names>MJ</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Variant interpretation: functional assays to the rescue</article-title>
<source/>Am J Hum Genet
          <year>2017</year>
<volume>101</volume>
<issue>3</issue>
<fpage>315</fpage>
<lpage>325</lpage>
<pub-id pub-id-type="pmid">28886340</pub-id>
</element-citation>
</ref>
</ref-list>
</back>
<floats-group>
<table-wrap id="t1-pgpm-11-121" position="float">
<label>Table 1</label>
<caption>
<p>Distribution of alleles and genotypes of <italic>GSK3B</italic> and <italic>AKT1</italic> polymorphisms in groups of remitters and non-remitters</p>
</caption>
<table frame="hsides" rules="groups">
<thead>
<tr>
<th align="left" colspan="1" rowspan="1" valign="top">Polymorphism, allele frequencies (%)<xref ref-type="table-fn" rid="tfn2-pgpm-11-121">*</xref></th>
<th align="left" colspan="1" rowspan="1" valign="top">Genotype, allele</th>
<th align="left" colspan="1" rowspan="1" valign="top">Remitters (%)</th>
<th align="left" colspan="1" rowspan="1" valign="top">Non-remitters (%)</th>
<th align="left" colspan="1" rowspan="1" valign="top">Hardy–Weinberg equilibrium (<italic>χ</italic><sup>2</sup>, <italic>p</italic>)</th>
<th align="left" colspan="1" rowspan="1" valign="top"><italic>χ</italic><sup>2</sup>, <italic>p</italic></th>
</tr>
</thead>
<tbody>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">
<bold>
<italic>GSK3B</italic>
</bold>
</td>
<td align="left" colspan="1" rowspan="1" valign="top"></td>
<td align="left" colspan="1" rowspan="1" valign="top"></td>
<td align="left" colspan="1" rowspan="1" valign="top"></td>
<td align="left" colspan="1" rowspan="1" valign="top"></td>
<td align="left" colspan="1" rowspan="1" valign="top"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top"></td>
<td align="left" colspan="1" rowspan="1" valign="top">T/T</td>
<td align="left" colspan="1" rowspan="1" valign="top">31.1</td>
<td align="left" colspan="1" rowspan="1" valign="top">15.8</td>
<td align="left" colspan="1" rowspan="1" valign="top"><italic>χ</italic><sup>2</sup><sub>1</sub> = 0.082, <italic>p</italic><sub>1</sub> = 0.775; <italic>χ</italic><sup>2</sup><sub>2</sub> = 0.139, <italic>p</italic><sub>2</sub> = 0.709</td>
<td align="left" colspan="1" rowspan="1" valign="top"><italic>χ</italic><sup>2</sup> = 6.022, <italic>p</italic> = 0.049</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">rs334558</td>
<td align="left" colspan="1" rowspan="1" valign="top">C/T</td>
<td align="left" colspan="1" rowspan="1" valign="top">50.3</td>
<td align="left" colspan="1" rowspan="1" valign="top">50.0</td>
<td align="left" colspan="1" rowspan="1" valign="top"></td>
<td align="left" colspan="1" rowspan="1" valign="top"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">T = 71.2</td>
<td align="left" colspan="1" rowspan="1" valign="top">C/C</td>
<td align="left" colspan="1" rowspan="1" valign="top">18.6</td>
<td align="left" colspan="1" rowspan="1" valign="top">34.2</td>
<td align="left" colspan="1" rowspan="1" valign="top"></td>
<td align="left" colspan="1" rowspan="1" valign="top"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="2" valign="top">C = 28.8</td>
<td align="left" colspan="1" rowspan="1" valign="top">T</td>
<td align="left" colspan="1" rowspan="1" valign="top">56.3</td>
<td align="left" colspan="1" rowspan="1" valign="top">40.8</td>
<td align="left" colspan="1" rowspan="1" valign="top"></td>
<td align="left" colspan="1" rowspan="1" valign="top"><italic>χ</italic><sup>2</sup> = 5.919, <italic>p</italic> = 0.015</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">C</td>
<td align="left" colspan="1" rowspan="1" valign="top">43.7</td>
<td align="left" colspan="1" rowspan="1" valign="top">59.2</td>
<td align="left" colspan="1" rowspan="1" valign="top"></td>
<td align="left" colspan="1" rowspan="1" valign="top"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">
<bold>
<italic>AKT1</italic>
</bold>
</td>
<td align="left" colspan="1" rowspan="1" valign="top"></td>
<td align="left" colspan="1" rowspan="1" valign="top"></td>
<td align="left" colspan="1" rowspan="1" valign="top"></td>
<td align="left" colspan="1" rowspan="1" valign="top"></td>
<td align="left" colspan="1" rowspan="1" valign="top"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top"></td>
<td align="left" colspan="1" rowspan="1" valign="top">G/G</td>
<td align="left" colspan="1" rowspan="1" valign="top">47.3</td>
<td align="left" colspan="1" rowspan="1" valign="top">55.0</td>
<td align="left" colspan="1" rowspan="1" valign="top"><italic>χ</italic><sup>2</sup><sub>1</sub> = 1.384, <italic>p</italic><sub>1</sub> = 0.239; <italic>χ</italic><sup>2</sup><sub>2</sub> = 3.265, <italic>p</italic><sub>2</sub> = 0.071</td>
<td align="left" colspan="1" rowspan="1" valign="top"><italic>χ</italic><sup>2</sup> = 1.366, <italic>p</italic> = 0.505</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">rs1130214</td>
<td align="left" colspan="1" rowspan="1" valign="top">G/T</td>
<td align="left" colspan="1" rowspan="1" valign="top">40.0</td>
<td align="left" colspan="1" rowspan="1" valign="top">30.0</td>
<td align="left" colspan="1" rowspan="1" valign="top"></td>
<td align="left" colspan="1" rowspan="1" valign="top"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">G = 72.2</td>
<td align="left" colspan="1" rowspan="1" valign="top">T/T</td>
<td align="left" colspan="1" rowspan="1" valign="top">12.7</td>
<td align="left" colspan="1" rowspan="1" valign="top">15.0</td>
<td align="left" colspan="1" rowspan="1" valign="top"></td>
<td align="left" colspan="1" rowspan="1" valign="top"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="2" valign="top">T = 27.8</td>
<td align="left" colspan="1" rowspan="1" valign="top">G</td>
<td align="left" colspan="1" rowspan="1" valign="top">67.3</td>
<td align="left" colspan="1" rowspan="1" valign="top">70.0</td>
<td align="left" colspan="1" rowspan="1" valign="top"></td>
<td align="left" colspan="1" rowspan="1" valign="top"><italic>χ</italic><sup>2</sup> = 0.219, <italic>p</italic> = 0.640</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">T</td>
<td align="left" colspan="1" rowspan="1" valign="top">32.7</td>
<td align="left" colspan="1" rowspan="1" valign="top">30.0</td>
<td align="left" colspan="1" rowspan="1" valign="top"></td>
<td align="left" colspan="1" rowspan="1" valign="top"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top"></td>
<td align="left" colspan="1" rowspan="1" valign="top">C/C</td>
<td align="left" colspan="1" rowspan="1" valign="top">72.7</td>
<td align="left" colspan="1" rowspan="1" valign="top">65.0</td>
<td align="left" colspan="1" rowspan="1" valign="top"><italic>χ</italic><sup>2</sup><sub>1</sub> = 0.539, <italic>p</italic><sub>1</sub> = 0.463; <italic>χ</italic><sup>2</sup><sub>2</sub> = 0.178, <italic>p</italic><sub>2</sub> = 0.673</td>
<td align="left" colspan="1" rowspan="1" valign="top"><italic>χ</italic><sup>2</sup> = 1.150, <italic>p</italic> = 0.563</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">rs3730358</td>
<td align="left" colspan="1" rowspan="1" valign="top">C/T</td>
<td align="left" colspan="1" rowspan="1" valign="top">24.2</td>
<td align="left" colspan="1" rowspan="1" valign="top">32.5</td>
<td align="left" colspan="1" rowspan="1" valign="top"></td>
<td align="left" colspan="1" rowspan="1" valign="top"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">C = 80.8</td>
<td align="left" colspan="1" rowspan="1" valign="top">T/T</td>
<td align="left" colspan="1" rowspan="1" valign="top">3.0</td>
<td align="left" colspan="1" rowspan="1" valign="top">2.5</td>
<td align="left" colspan="1" rowspan="1" valign="top"></td>
<td align="left" colspan="1" rowspan="1" valign="top"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="2" valign="top">T = 19.2</td>
<td align="left" colspan="1" rowspan="1" valign="top">C</td>
<td align="left" colspan="1" rowspan="1" valign="top">84.8</td>
<td align="left" colspan="1" rowspan="1" valign="top">81.2</td>
<td align="left" colspan="1" rowspan="1" valign="top"></td>
<td align="left" colspan="1" rowspan="1" valign="top"><italic>χ</italic><sup>2</sup> = 0.625, <italic>p</italic> = 0.429</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">T</td>
<td align="left" colspan="1" rowspan="1" valign="top">15.2</td>
<td align="left" colspan="1" rowspan="1" valign="top">18.8</td>
<td align="left" colspan="1" rowspan="1" valign="top"></td>
<td align="left" colspan="1" rowspan="1" valign="top"></td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="tfn1-pgpm-11-121">
<p><bold>Notes:</bold> Numbers 1 and 2 in subscript represent group of remitters and group of non-remitters, respectively.</p>
</fn>
<fn id="tfn2-pgpm-11-121">
<label>*</label>
<p>The allele frequencies are in the reference population of 198 Utah (USA) residents with Northern and Western European ancestry, as listed in the 1000 Genomes Project, Phase 3 (population CEU).</p>
</fn>
</table-wrap-foot>
</table-wrap>
<table-wrap id="t2-pgpm-11-121" position="float">
<label>Table 2</label>
<caption>
<p>Distribution of alleles and genotypes of rs334558 in groups of remitters and non-remitters (selective serotonin inhibitors only)</p>
</caption>
<table frame="hsides" rules="groups">
<thead>
<tr>
<th align="left" colspan="1" rowspan="1" valign="top">Polymorphism</th>
<th align="left" colspan="1" rowspan="1" valign="top">Genotype, allele</th>
<th align="left" colspan="1" rowspan="1" valign="top">Remitters (%)</th>
<th align="left" colspan="1" rowspan="1" valign="top">Non-remitters (%)</th>
<th align="left" colspan="1" rowspan="1" valign="top">Hardy–Weinberg equilibrium (<italic>χ</italic><sup>2</sup>, <italic>p</italic>)</th>
<th align="left" colspan="1" rowspan="1" valign="top"><italic>χ</italic><sup>2</sup>, <italic>p</italic></th>
</tr>
</thead>
<tbody>
<tr>
<td align="left" colspan="1" rowspan="5" valign="top">rs334558</td>
<td align="left" colspan="1" rowspan="1" valign="top">T/T</td>
<td align="left" colspan="1" rowspan="1" valign="top">33.7</td>
<td align="left" colspan="1" rowspan="1" valign="top">14.3</td>
<td align="left" colspan="1" rowspan="2" valign="top"><italic>χ</italic><sup>2</sup><sub>1</sub> = 0.001, <italic>p</italic><sub>1</sub> = 0.975; <italic>χ</italic><sup>2</sup><sub>2</sub> = 0.159, <italic>p</italic><sub>2</sub> = 0.690</td>
<td align="left" colspan="1" rowspan="2" valign="top"><italic>χ</italic><sup>2</sup> = 4.248, <italic>p</italic> = 0.120</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">C/T</td>
<td align="left" colspan="1" rowspan="1" valign="top">48.8</td>
<td align="left" colspan="1" rowspan="1" valign="top">52.4</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">C/C</td>
<td align="left" colspan="1" rowspan="1" valign="top">17.4</td>
<td align="left" colspan="1" rowspan="1" valign="top">33.3</td>
<td align="left" colspan="1" rowspan="1" valign="top"></td>
<td align="left" colspan="1" rowspan="1" valign="top"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">T</td>
<td align="left" colspan="1" rowspan="1" valign="top">58.1</td>
<td align="left" colspan="1" rowspan="1" valign="top">40.5</td>
<td align="left" colspan="1" rowspan="1" valign="top"></td>
<td align="left" colspan="1" rowspan="1" valign="top"><italic>χ</italic><sup>2</sup> = 4.250, <italic>p</italic> = 0.039</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">C</td>
<td align="left" colspan="1" rowspan="1" valign="top">41.9</td>
<td align="left" colspan="1" rowspan="1" valign="top">59.5</td>
<td align="left" colspan="1" rowspan="1" valign="top"></td>
<td align="left" colspan="1" rowspan="1" valign="top"></td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="tfn3-pgpm-11-121">
<p><bold>Note:</bold> Numbers 1 and 2 in subscript represent group of remitters and group of non-remitters, respectively.</p>
</fn>
</table-wrap-foot>
</table-wrap>
</floats-group>
</article>
</pmc-articleset>